A study to evaluate effects of tafamdis on exercise capacity, cardiac function and myocardial amyloid deposition in patients with transthyretin amyloid cardiomyopathy
Latest Information Update: 01 Dec 2021
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Therapeutic Use
- 30 Oct 2020 New trial record
- 01 Sep 2020 Results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology